Skip to content

The Effect of Footwear Generated Biomechanical Manipulation on Symptoms of Stress Urinary Incontinence

The Effect of Footwear Generated Biomechanical Manipulation on Symptoms of Stress Urinary Incontinence

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03194789
Acronym
SUI
Enrollment
64
Registered
2017-06-21
Start date
2017-11-29
Completion date
2023-12-12
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Floor Disorders, Stress Urinary Incontinence

Keywords

FGBMM, LPSE, UDI - 6, UIQ - 7

Brief summary

FGBMM (footwear generated biomechanical manipulation) effects neuromuscular patterns of pelvic muscles. While there have been no published studies to our knowledge investigating the effect of FGBMM on urinary incontinence, FGBMM causes perturbations in balance and gait that create dynamics similar to dynamic lumbosacral stabilization exercises. The investigators propose that FGBMM induces the same bio-mechanical improvements as LPSE (lumbopelvic stabilization exercises) which have shown benefit for incontinence. Instead of instructing patients to co-contract the lower trunk and pelvic floor muscles as commonly done for LPSE, the shoes used in FGBMM can be calibrated in a way that causes this co-contraction to occur without the patient realizing. Beneficial pelvis and spine positioning can also be accomplished by strategic placement of the pods without having to instruct the patient on complicated maneuvers. Capitalizing on the excellent adherence and clinical benefits of FGBMM on related conditions, the investigators propose to evaluate the effects of FGBMM in addition to pelvic floor therapy for improving the symptoms of stress urinary incontinence in an urban inner city population.

Detailed description

FGBMM (footwear generated biomechanical manipulation) effects neuromuscular patterns of pelvic muscles. While there have been no published studies to our knowledge investigating the effect of FGBMM on urinary incontinence, FGBMM has been shown to cause perturbations in balance and gait that create dynamics similar to dynamic lumbosacral stabilization exercises. In support of this theory, although not published, one of the founders of the technique, Avi Elbaz, has noted anecdotal evidence that patients who had SUI (stress urinary incontinence) and underwent FGBMM for knee or low back pain reported improvement of incontinence. The investigators propose that FGBMM induces the same bio-mechanical improvements as LPSE (lumbopelvic stabilization exercises) which have shown benefit for incontinence. The pods on the footwear can be positioned to challenge the patients balance in a manner similar to the way trampolines are utilized in LPSE. Instead of instructing patients to co-contract the lower trunk and pelvic floor muscles as commonly done for LPSE, the shoes used in FGBMM can be calibrated in a way that causes this co-contraction to occur without the patient realizing. Beneficial pelvis and spine positioning can also be accomplished by strategic placement of the pods without having to instruct the patient on complicated maneuvers. An additional advantage of FGBMM is that this exercise is done with increased intra-abdominal pressure mimicking the condition and the setting when incontinence occurs rather than static exercise that is used in PFT. While performing regular activities, people are naturally squatting and doing other activities that increase intra-abdominal pressure. Furthermore, FGBMM is more practical for people with busy schedules because it can be accomplished with a much smaller time commitment from the patient than traditional PFT since it is done during normal activity. Capitalizing on the excellent adherence and clinical benefits of FGBMM on related conditions, the investigators propose to evaluate the effects of FGBMM in addition to pelvic floor therapy for improving the symptoms of stress urinary incontinence in an urban inner city population. A potential use of FGBMM using shoes as a addition to traditional pelvic floor therapy may yield a more effective therapy with better adherence. Problems with traditional therapy include poor patient adherence (patients often do not complete the sessions and have poor adherence (about 50%), lack of the continuation in an ongoing program, leading to relapse and need for re treatment or even little clinical benefit. Additionally, access to pelvic floor therapy is limited for many patients since there are not enough available outpatient therapy services to meet the needs of all patients. Finding an additional exercise program that will increase adherence and improve patient outcomes with better clinical benefits is a high priority from both patient care and cost management perspectives. FGBMM using shoes potentially overcomes many of these issues with improving/modifying abnormal biomechanics of pelvic floor muscles (therefore decreasing incontinence), and a home based exercise program utilizing footwear that causes exercise with normal activity by promoting perturbation. This bio-mechanical approach may significantly improve the symptoms of urinary incontinence in patients with Stress SUI or Mixed urinary incontinence. Capitalizing on the reported excellent adherence and clinical benefit of FGBMM in patients with related conditions, the investigators propose to evaluate the bio-mechanical exercise (wearing an appropriately calibrated shoe at home for a prescribed amount of time each day) as a conservative treatment that may supplement traditional pelvic floor therapy, medications and even surgical intervention for the same in an inner urban city population.

Interventions

DEVICEFootwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy

Participants will have FGBMM using shoes with pertupods along with traditional PFPT over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.

OTHERTraditional Pelvic Floor Therapy

Participant will receive six sessions of PFPT, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.

Sponsors

Montefiore Medical Center
Lead SponsorOTHER
Apos Medical and Sports Technology Ltd.
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants were randomized to the two arms/groups in a 1:1 ratio. To ensure balance in treatment assignment, a block randomization method was employed. Participants were randomized to either the traditional PFPT group or the dual therapy (PFPT + FGBMD) group using permuted blocks of size 4. This means that within each block of four consecutively enrolled participants, two were randomly assigned to each treatment group. The block assignments were generated using a random number sequence, ensuring that the allocation sequence was unpredictable.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Stress or Mixed Urinary Incontinence, based on UDI-6. * Females between the ages of 18-75 years. * Weight less than 350 lbs. * Ambulatory and active patients that can participate in a rehabilitation program that includes daily walking * Able to walk at least 50 meters and scored positive on the STEADI test * Able to understand, read and sign the informed consent form * English or Spanish speaking

Exclusion criteria

* Prior surgery for incontinence * Pelvic Floor Therapy within past 6 months. * Currently pregnant * Predominantly Urge Incontinence. * Patients with more than 3 falls in the last 52 weeks, OR any balance related fall with an injury in the last 52 weeks. * Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure. * Patients with a history of pathological osteoporotic fracture * Any major cardiovascular comorbidities prohibiting enrollment in an active exercise program * Active heart disease (ischemia or heart failure admissions within 24 weeks) and Active COPD (exacerbation within 24 weeks) * Active malignancies on ongoing treatment * Patient with neurological gait pattern. * Patient requiring assistive device during gait analysis.

Design outcomes

Primary

MeasureTime frameDescription
Severity of Stress Urinary Incontinence (SUI) SymptomsBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)Severity of SUI symptoms was measured using the six-item Urogenital Distress Inventory (UDI-6). The UDI-6 is a validated, patient-reported questionnaire which assesses the severity of symptoms of urinary incontinence. It includes questions evaluating the frequency of urination, incontinence/leakage, difficulty with complete bladder emptying, and pain. Responses on the UDI-6 are rated on a 5-point scale ranging from 0 ("No/Not present") to 4 ("Quite a bit"). Raw scores were summed, averaged, and multiplied by 25 to yield a final score scale ranging from 0-100. Higher scores are indicative of greater distress due to symptom severity. Results are summarized by study arm.

Secondary

MeasureTime frameDescription
Quality of Life as Determined by the Urinary Impact Questionnaire (UIQ-7)Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)Quality of Life will be determined with the use of the UIQ-7 subscale component of the Pelvic Floor Impact Questionnaire-short form 7 (PFIQ-7) questionnaire. Specifically, the UIQ-7 questions within the PFIQ-7 are used to assess the impact of bladder or urine symptoms or conditions on a participant's daily function and activities, social health, or mental health over the prior 3 months. Participants provide responses for each question on 4-point scale ranging from 0 ("Not at all") to 3 ("Quite a bit"). Mean scores are averaged and multiplied by 100/3 to yield an overall possible score of 0-100, such that higher scores are indicative of a greater negative impact on quality of life from pelvic floor dysfunction. Scores are summarized by study arm using basic descriptive statistics.
Pelvic Floor Muscle (PFM) Activity - Average ContractionBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFM average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average contraction results values are summarized by study arm using basic descriptive statistics.
Pelvic Floor Muscle (PFM) Activity - Maximum ContractionBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Maximum contraction results values are summarized by study arm using basic descriptive statistics.
Pelvic Floor Muscle (PFM) Activity - Average RestBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average rest results values are summarized by study arm using basic descriptive statistics.
Pelvic Floor Muscle (PFM) Activity - Change From Average Contraction to Average RestBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Change From Average Contraction to Average Rest results values are summarized by study arm using basic descriptive statistics.
Pelvic Floor Muscle (PFM) Activity - Average Abdominal ContractionBaseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average Abdominal Contraction results values are summarized by study arm using basic descriptive statistics.
Adherence to TreatmentBaseline to 24 weeks (~Six months)Adherence to FGBMM and PFPT was assessed based on self-reporting of in-person PFPT visits and in-person calibration visits (Dual Therapy study arm only) on an end of study questionnaire. Median number of visits is calculated and summarized by study arm.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAnna M Lasak, MD

Montefiore Medical Center

Participant flow

Recruitment details

The study included women with stress and mixed urinary incontinence referred for physical therapy from obstetrics, gynecology, urogynecology, and urology. Patients were evaluated by a physiatrist and screened for eligibility. Recruitment occurred at Montefiore Health System from November 2017 to December 2023, with the first participant enrolled on November 29, 2017, and the last on March 2, 2023.

Pre-assignment details

Of 121 patients that were screened for eligibility, 64 met the inclusion criteria and were randomized into either the FGBMM plus Traditional PFPT group or the Traditional PFPT group.

Baseline characteristics

Characteristic
Age, Customized56.0 years
STANDARD_DEVIATION 12.7
BMI30.7 kg/m^2
Ethnicity (NIH/OMB)
Hispanic or Latino
16 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
Race/Ethnicity, Customized
American Indian / Alaskan
1 Participants
Race/Ethnicity, Customized
Asian
5 Participants
Race/Ethnicity, Customized
Black / African American
15 Participants
Race/Ethnicity, Customized
Declined / Unknown
4 Participants
Race/Ethnicity, Customized
Other
14 Participants
Race/Ethnicity, Customized
Other Pacific Islander
1 Participants
Race/Ethnicity, Customized
White
3 Participants
Region of Enrollment
United States
33 participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
0 Participants
Type of Incontinence
Mixed Incontinence
39 Participants
Type of Incontinence
Stress Incontinence
25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 310 / 33
other
Total, other adverse events
3 / 318 / 33
serious
Total, serious adverse events
0 / 310 / 33

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026